Next Article in Journal
Histamine Intolerance—A Kind of Pseudoallergic Reaction
Next Article in Special Issue
The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study
Previous Article in Journal
Applications of Single-Cell Sequencing Technology to the Enteric Nervous System
Previous Article in Special Issue
Tumor Suppressor Role of Wild-Type P53-Dependent Secretome and Its Proteomic Identification in PDAC
Review

Cross-Talk between p53 and Wnt Signaling in Cancer

1
Department of Medicine II, Mannheim University Hospital, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany
2
Division Signaling and Functional Genomics, German Cancer Research Center (DKFZ), and Department Cell and Molecular Biology, Faculty of Medicine Mannheim, Heidelberg University, D-69120 Heidelberg, Germany
3
Mannheim Cancer Center, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany
4
DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Gabriella D’Orazi
Biomolecules 2022, 12(3), 453; https://doi.org/10.3390/biom12030453
Received: 18 February 2022 / Revised: 11 March 2022 / Accepted: 12 March 2022 / Published: 15 March 2022
(This article belongs to the Collection p53 Function and Dysfunction in Human Health and Diseases)
Targeting cancer hallmarks is a cardinal strategy to improve antineoplastic treatment. However, cross-talk between signaling pathways and key oncogenic processes frequently convey resistance to targeted therapies. The p53 and Wnt pathway play vital roles for the biology of many tumors, as they are critically involved in cancer onset and progression. Over recent decades, a high level of interaction between the two pathways has been revealed. Here, we provide a comprehensive overview of molecular interactions between the p53 and Wnt pathway discovered in cancer, including complex feedback loops and reciprocal transactivation. The mutational landscape of genes associated with p53 and Wnt signaling is described, including mutual exclusive and co-occurring genetic alterations. Finally, we summarize the functional consequences of this cross-talk for cancer phenotypes, such as invasiveness, metastasis or drug resistance, and discuss potential strategies to pharmacologically target the p53-Wnt interaction. View Full-Text
Keywords: Wnt; p53; APC; beta-catenin; drug resistance; cancer; metastasis Wnt; p53; APC; beta-catenin; drug resistance; cancer; metastasis
Show Figures

Figure 1

MDPI and ACS Style

Xiao, Q.; Werner, J.; Venkatachalam, N.; Boonekamp, K.E.; Ebert, M.P.; Zhan, T. Cross-Talk between p53 and Wnt Signaling in Cancer. Biomolecules 2022, 12, 453. https://doi.org/10.3390/biom12030453

AMA Style

Xiao Q, Werner J, Venkatachalam N, Boonekamp KE, Ebert MP, Zhan T. Cross-Talk between p53 and Wnt Signaling in Cancer. Biomolecules. 2022; 12(3):453. https://doi.org/10.3390/biom12030453

Chicago/Turabian Style

Xiao, Qiyun, Johannes Werner, Nachiyappan Venkatachalam, Kim E. Boonekamp, Matthias P. Ebert, and Tianzuo Zhan. 2022. "Cross-Talk between p53 and Wnt Signaling in Cancer" Biomolecules 12, no. 3: 453. https://doi.org/10.3390/biom12030453

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop